A STUDY OF THE CORRELATION BETWEEN MORPHOLOGICAL FINDINGS AND BIOLOGICAL ACTIVITIES IN CLINICALLY NONFUNCTIONING PITUITARY ADENOMAS

OBJECTIVEThe aims of this study are to review the histology of the clinically nonfunctioning pituitary adenomas (CNFPAs) we have observed and to determine whether or not the frequency of cavernous sinus invasion is different among each type of morphology. METHODSIn addition, several proliferative markers, including Ki67, p53, E-cadherin, matrix metallo-proteinase 9 and pituitary tumor derived fibroblast growth factor receptor 4 (ptd-FGFR4), were also investigated in invasive and non-invasive tumors. RESULTSOur consequent 213 CNFPAs were diagnosed as follows: 64% were silent gonadotroph adenomas, 18% were null cell adenomas, 12% were silent corticotroph adenomas, 4% were silent Subtype 3 adenomas, and 1% were other types of adenomas. Female patients or younger patients showed a significant preponderance in silent corticotroph adenomas and in silent Subtype 3 adenomas, respectively. Cavernous sinus invasion occurs most frequently in silent corticotroph adenomas (85%) followed by Subtype 3 adenomas (67%), null cell adenomas (38%), and silent gonadotroph adenomas (11%). There were no significant differences in the Ki67, p53, E-cadherin, matrix metallo-proteinase 9, and ptd-FGFR4 expression between tumors with and without cavernous sinus invasion. CONCLUSIONFrom a clinical standpoint, it is quite important to differentiate morphological type in CNFPAs to aid the clinician in assessing the clinical behavior and prognosis of the tumor. Therefore, we suggest that all CNFPAs be examined not only by conventional light microscopy but also by immunohistochemistry, preferably by electron microscopy, to achieve a correct morphological diagnosis.

[1]  L. Pan,et al.  Magnetic resonance imaging and biological markers in pituitary adenomas with invasion of the cavernous sinus space , 2005, Journal of Neuro-Oncology.

[2]  J. Ahlquist,et al.  A spectrum of behaviour in silent corticotroph pituitary adenomas , 2005, British journal of neurosurgery.

[3]  K. Kovacs,et al.  Silent Adenoma Subtype 3 of the Pituitary—Immunohistochemical and Ultrastructural Classification: A Review of 29 Cases , 2005, Ultrastructural pathology.

[4]  J. Hainfellner,et al.  Expression of cell proliferation markers in pituitary adenomas – correlation and clinical relevance of MIB-1 and anti-topoisomerase-IIα , 2004, Acta Neurochirurgica.

[5]  Z. Qian,et al.  Cytoplasmic expression of fibroblast growth factor receptor-4 in human pituitary adenomas: relation to tumor type, size, proliferation, and invasiveness. , 2004, The Journal of clinical endocrinology and metabolism.

[6]  D. Okonkwo,et al.  Clinical Characteristics of Silent Corticotrophic Adenomas and Creation of an Internet-accessible Database to Facilitate Their Multi-institutional Study , 2003, Neurosurgery.

[7]  W. Wilczak,et al.  Expression of serine proteases and metalloproteinases in human pituitary adenomas and anterior pituitary lobe tissue , 2003, Acta Neuropathologica.

[8]  I. McCutcheon,et al.  p53 and MIB-1 Immunohistochemistry as Predictors of the Clinical Behavior of Nonfunctioning Pituitary Adenomas , 2003, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[9]  Y. Segev,et al.  Postoperative surveillance of clinically nonfunctioning pituitary macroadenomas: markers of tumour quiescence and regrowth , 2003, Clinical endocrinology.

[10]  A. Tabarin,et al.  Polysialylated neural cell adhesion molecules expressed in human pituitary tumors and related to extrasellar invasion. , 2003, Journal of neurosurgery.

[11]  J. Wass,et al.  Non‐functioning pituitary adenomas with positive immunoreactivity for ACTH behave more aggressively than ACTH immunonegative tumours but do not recur more frequently , 2003, Clinical endocrinology.

[12]  J. Kuratsu,et al.  Are Nonfunctioning Pituitary Adenomas Extending into the Cavernous Sinus Aggressive and/or Invasive? , 2001, Neurosurgery.

[13]  L. Mastronardi,et al.  Lack of correlation between Ki-67 labelling index and tumor size of anterior pituitary adenomas , 2001, BMC Cancer.

[14]  R. Macaulay,et al.  Absent p53 Immunohistochemical Staining in a Pituitary Carcinoma , 2001, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[15]  B. Scheithauer,et al.  Clinically Silent Corticotroph Tumors of the Pituitary Gland , 2000, Neurosurgery.

[16]  K. Kurisu,et al.  Expression of epithelial cadherin and cavernous sinus invasion in human pituitary adenomas , 1997, Journal of Neuro-Oncology.

[17]  I. Chiodini,et al.  Nonfunctioning adenomas of the pituitary. , 1996, Metabolism: Clinical and Experimental.

[18]  B. Scheithauer,et al.  Gonadotroph adenoma of the pituitary gland: a clinicopathologic analysis of 100 cases. , 1996, Mayo Clinic proceedings.

[19]  B. Scheithauer,et al.  p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. , 1996, Neurosurgery.

[20]  C. Matula,et al.  Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. , 1993, Neurosurgery.

[21]  C. Matula,et al.  Pituitary Adenomas with Invasion of the Cavernous Sinus Space , 1993 .

[22]  S. Asa,et al.  Clinically Non-Functioning Human Pituitary Adenomas , 1992, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[23]  K. Kovacs,et al.  Ultrastructural diagnosis of human pituitary adenomas , 1992, Microscopy research and technique.

[24]  K. Kovacs,et al.  Morphological study of clinically nonsecreting pituitary adenomas in patients under 40 years of age. , 1991, Journal of neurosurgery.

[25]  E. Knosp,et al.  Proliferation activity in pituitary adenomas: measurement by monoclonal antibody Ki-67. , 1989, Neurosurgery.

[26]  T. H. Newton,et al.  MR imaging of cavernous sinus involvement by pituitary adenomas. , 1988, AJR. American journal of roentgenology.

[27]  B. Scheithauer,et al.  Pathology of invasive pituitary tumors with special reference to functional classification. , 1986, Journal of neurosurgery.

[28]  B. Scheithauer,et al.  The occurrence of dural invasion in pituitary adenomas. , 1986, Journal of neurosurgery.

[29]  Gillian E. Wu,et al.  Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. , 2002, The Journal of clinical investigation.

[30]  B. Scheithauer,et al.  Pathology of Pituitary Adenomas and Pituitary Hyperplasia , 2001 .

[31]  B. Scheithauer,et al.  Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. , 1996, Neurosurgery.